Evidence map›Paper›PMID 42441401›Full record

ArticleCell reports2026

Aortic valve stenosis serum IGFBP2 mediates female-specific Evogliptin resistance in valve myofibroblasts.

Brandon J Vogt, Megan Chavez, Nicole E Félix Vélez, Rayyan M Gorashi, Ryan R Reeves, Brian A Aguado

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cell reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

6 authors.

Brandon J VogtShu Chien-Gene Lay Department of Bioengineering, University of California, San Diego, La Jolla, CA, USA; Sanford Consortium for Regenerative Medicine, La Jolla, CA, USA.
Megan ChavezShu Chien-Gene Lay Department of Bioengineering, University of California, San Diego, La Jolla, CA, USA; Sanford Consortium for Regenerative Medicine, La Jolla, CA, USA.
Nicole E Félix VélezShu Chien-Gene Lay Department of Bioengineering, University of California, San Diego, La Jolla, CA, USA; Sanford Consortium for Regenerative Medicine, La Jolla, CA, USA.
Rayyan M GorashiShu Chien-Gene Lay Department of Bioengineering, University of California, San Diego, La Jolla, CA, USA; Sanford Consortium for Regenerative Medicine, La Jolla, CA, USA.
Ryan R ReevesSulpizio Cardiovascular Center, University of California, San Diego, La Jolla, CA, USA.
Brian A AguadoShu Chien-Gene Lay Department of Bioengineering, University of California, San Diego, La Jolla, CA, USA; Sanford Consortium for Regenerative Medicine, La Jolla, CA, USA; Program in Materials Science and Engineering, University of California, San Diego, La Jolla, CA, USA. Electronic address: baguado@ucsd.edu.

Funding

Probing sex differences in myocardial fibrosis at multiple length scales using biomaterialsDP2HL173948 · NHLBI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Brian Alberto Aguado · 2023 to 2026
$2.4M
Investigating sex differences in persistent valvular myofibroblast activation using hydrogel culture substratesR00HL148542 · NHLBI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI AGUADO, BRIAN ALBERTO · 2021 to 2023
$1.1M
Decoupling sex chromosome and sex hormone regulation of cardiac myofibroblast activationF31HL176153 · NHLBI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Rayyan Gorashi · 2024 to 2026
$85k
NHLBI NIH HHS DP2 HL173948NHLBI NIH HHS F31 HL176153NHLBI NIH HHS R00 HL148542
6 · The paper itself

Abstract

Aortic valve stenosis (AVS) is a sexually dimorphic cardiovascular disease characterized by fibro-calcification of the aortic valve leaflet. Sex differences in AVS arise in part from sexually dimorphic serum composition that differentially regulates valvular interstitial cell (VIC) myofibroblast activation. However, how individual serum factors contribute to sex-specific drug responses remains unknown. Here, we integrate serum proteomic profiling with in vitro drug screening using hydrogel biomaterials to identify sex-specific regulators of antifibrotic drug efficacy. We found that serum insulin-like growth factor binding protein 2 (IGFBP2) mediates Evogliptin resistance in female VICs cultured with female AVS serum through the activation of Rho/ROCK and focal adhesion kinase signaling. Our findings highlight IGFBP2 as a candidate biomarker for stratifying female patients with AVS for Evogliptin treatment, underscoring the need to incorporate sex as a biological variable in determining AVS treatments.

Indexed as

Aortic ValveAortic Valve StenosisDrug ResistanceInsulin-Like Growth Factor Binding Protein 2MyofibroblastsAnimalsFemaleHumansMaleSignal TransductionIGFBP2 protein, humanInsulin-Like Growth Factor Binding Protein 2aortic valve stenosisbiomarkerCP: cell biologyevogliptinfibroblasthydrogelsigf1igfbp2proteomicsserumsex differences

Identifiers

PMID42441401
PMCPMC13476089

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.